Lund, Sverige, 18:00 CET, 1 March 2019 – Pursuant to the authorizations granted by the annual general meeting on 22 May 2018, the board of directors of BONESUPPORT HOLDING AB (”BONESUPPORT”) has resolved to issue and immediately thereafter repurchase 505,000 series C shares. The shares are issued and repurchased in accordance with the share saving programs LTI 2018 and Board LTI 2018, which were adopted by the annual general meeting on 22 May 2018.
Pursuant to the authorizations granted by the annual general meeting on 22 May 2018, the board of directors of BONESUPPORT has resolved to issue 505,000 series C shares to Svenska Handelsbanken AB. The subscription price per share amounts to SEK 0.625, which corresponds to the quota value of the shares. Furthermore, the board of directors has resolved to immediately repurchase all 505,000 series C shares from Svenska Handelsbanken AB at a price corresponding to the subscription price.
The purpose of the issue and repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of performance shares to employees within the group and certain members of the board of directors of BONESUPPORT who are participating in the share saving programs LTI 2018 and Board LTI 2018, which were adopted by the annual general meeting on 22 May 2018. Allotment of performance shares shall take place within 30 days from the publication of the year-end report for the financial year 2021.
Since previously, BONESUPPORT holds no series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT® and CERAMENT® are registered trademarks.
For more information contact:
BONESUPPORT HOLDING AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46(0) 46 286 53 70
This information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CET on 1 March 2019.